HOME >> MEDICINE >> NEWS
New data supports CellCept's position as a world leader in solid organ transplantation

m creatinine levels were observed over two years, reinforcing CellCept's nephroprotective profile.

Grostzner J, Kaczmarek I, Mueller M, et al. Calcineurin-inhibitor-free immunosuppression with mycophenolate mofetil and sirolimus after cardiac transplantation is safe and improves renal function significantly: 1 year follow-up. Abstract 449, ATC 2004.
In this study of 30 heart transplant patients data showed that conversion from a CNI-based immunosuppressant regimen to CellCept and sirolimus in patients with chronic kidney failure is safe, preserves graft function and improves kidney function. This may help avoid CNI-related nephrotoxicity, a common problem after heart transplantation, which can lead to increased morbidity and impairment of patients' quality of life.

in adult kidney transplant patients
Abramowicz D, Gafner N, Wijngaard P. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomised study. Abstract 1527, ATC 2004.
In a study of 151 stable renal transplant patients, where CNI was withdrawn from a CellCept-based immunosuppressant regimen, there was no impact on five-year graft and patient survival. Beneficial effects were observed in kidney function, as well as lipid profile, blood pressure and malignancy rate. These data show that CellCept is safe to use long term as part of a low-toxicity immunosuppressant regimen and allows CNI-sparing, thus avoiding associated kidney toxicity, high cholesterol and high blood pressure, which can lead to impaired graft function.

Kessler M, Frimat L, Charpentier B, et al. Renal function evaluation after half dose reduction of Neoral in combination with CellCept in renal transplant patients with altered renal function: preliminary 2 year safety and efficacy results of the MMF REFERENCE study: a randomised, open, multicentre, prospective, controlled study. Abstract 462, ATC 20
'"/>

Contact: Cendrine Banerjee-Quetel
cendrine.banerjee-quetel@ketchum.com
44-207-611-3656
Ketchum
19-May-2004


Page: 1 2 3 4 5

Related medicine news :

1. Emergency department study supports giving dehydrated children fluids by mouth
2. Review supports link between HRT and stroke
3. Chamomile tea: New evidence supports health benefits
4. Social supports lessen effects of maltreatment on children vulnerable to depression
5. Study supports the use of mechanical assistance
6. Study supports aggressive treatment of heart patients with cholesterol-lowering medication
7. NCI grant supports Jefferson trial to study test for colorectal cancer recurrence
8. Study supports new theory for nicotines protective effect against neurodegenerative disorders
9. New study supports use of PET scans in early diagnosis of Alzheimers disease
10. Contraception study supports convenience, simplicity
11. International grant supports study related to preventing organ rejection

Post Your Comments:
(Date:7/24/2014)... night, which shuts off nighttime production of the hormone ... widely used breast cancer drug, says a new study ... study, "Circadian and Melatonin Disruption by Exposure to Light ... Breast Cancer," published in the journal Cancer Research ... vital to the success of tamoxifen in treating breast ...
(Date:7/24/2014)... Ticket Down is a reliable source for cheap ... Sports Authority Field on July 26th. For the past four years, ... of the best club teams from around the world to North ... about weeks after its completion, fans – new and old alike ... stars in the world compete. Some of these players were already ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Four ... this month of its $3 million renovation of the ... Lokelani presidential/residential three-bedroom suites, just in time to welcome ... , With design direction from the internationally-acclaimed BraytonHughes Design ... largest on the property and the largest in Hawaii—received ...
(Date:7/24/2014)... In a July 9th article in the ... Lotus Blossom Consulting LLC , was quoted in a ... to Cut the High Cost of Infertility . Her advice ... to maximize your chance of success from the first attempt.” ... , “I am always happy to talk with the ...
(Date:7/24/2014)... County, NJ (PRWEB) July 24, 2014 ... a leading specialist in hematology and oncology, Dr. ... Medical Group. Our system welcomes Dr. Upadhyaya to ... physicians comprise CarePoint Health Medical Group, a comprehensive ... County, representing a wide range of specialties. This ...
Breaking Medicine News(10 mins):Health News:Total darkness at night is key to success of breast cancer therapy -- Tulane study 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 3Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 2Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 3Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 4Health News:Four Seasons Resort Maui's Newly Designed Top Suites Debut 5Health News:Mindy Berkson, Infertility Expert and Founder, Lotus Blossom Consulting LLC: Leading the Pathway to Parenthood 2Health News:Mindy Berkson, Infertility Expert and Founder, Lotus Blossom Consulting LLC: Leading the Pathway to Parenthood 3Health News:Dr. Upadhyaya Joins CarePoint Health Medical Group 2
(Date:7/24/2014)... PLAINFIELD, N.J. , July 24, 2014  PTC ... that the Company will host a webcast conference call ... provide an update on the company,s business and outlook ... before the opening of the market. ... (domestic) or (973) 935-8152 (international) five minutes prior to ...
(Date:7/24/2014)... 2014  Abaxis, Inc. (NasdaqGS: ABAX ), ... today reported financial results for the first fiscal quarter ... , Revenues of $47.5 million, up 10% over ... $0.21, up 50% over last year,s comparable quarter. ... $7.2 million, up 20% over last year,s comparable quarter. ...
(Date:7/24/2014)... 2014 IGI Laboratories, Inc. (NYSE MKT: IG), ... generic pharmaceutical company, today announced it has accepted  ... Mr. Finio has accepted a senior level finance position ... his acceptance of his new position, Mr. Finio will ... for IGI Laboratories, Inc.  The effective date of his ...
Breaking Medicine Technology:Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2
Cached News: